Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Repare Therapeutics Inc
(NQ:
RPTX
)
3.200
+0.050 (+1.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
71,408
Open
3.180
Bid (Size)
3.110 (4)
Ask (Size)
3.540 (1)
Prev. Close
3.150
Today's Range
3.110 - 3.240
52wk Range
2.980 - 13.85
Shares Outstanding
42,088,446
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
April 26, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
April 15, 2024
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx.
Via
Benzinga
Performance
YTD
-56.10%
-56.10%
1 Month
-32.06%
-32.06%
3 Month
-52.52%
-52.52%
6 Month
-0.62%
-0.62%
1 Year
-64.29%
-64.29%
More News
Read More
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 21, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Recap: Repare Therapeutics Q4 Earnings
February 28, 2024
Via
Benzinga
Recap: Repare Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
March 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
February 29, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm
February 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)
February 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
February 15, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
February 13, 2024
Via
Benzinga
Repare Therapeutics to Regain Global Rights to Camonsertib
February 12, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
January 25, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
January 08, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
January 04, 2024
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
December 29, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
November 15, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
These Biotech Stocks Could Double Your Money, According To Analysts
November 09, 2023
Via
Benzinga
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
November 09, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
November 07, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
November 06, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 06, 2023
Via
Benzinga
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
November 06, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
October 13, 2023
From
Repare Therapeutics Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.